<div><div></div><div>Abbott reported first-quarter 2026 results with net sales of $11.164 billion and GAAP diluted EPS of $0.61; adjusted diluted EPS was $1.15, up 6% year-over-year. The company completed its acquisition of Exact Sciences on March 23, 2026, and updated full-year 2026 guidance to comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58 (including $0.20 of dilution from the acquisition). Abbott also declared its quarterly dividend of $0.63 per share. Financial Highlights <ul><li>Revenue (Net Sales) — $11,164 million for Q1 2026, a 7.8% increase versus Q1 2025.</li><li>Gross margin (as reported) — Gross margin reported at $5,852 million for Q1 2026; adjusted gross margin excluding intangible amortization and other specified items shown as $6,284 million.</li><li>Operating earnings (Operating income) — $1,345 million for Q1 2026 (operating earnings declined vs. prior year).</li><li>Net earnings — GAAP net earnings of $1,077 million for Q1 2026; net earnings excluding specified items of $2,022 million.</li><li>Diluted EPS — GAAP diluted EPS $0.61; diluted EPS excluding specified items $1.15 (5.5% growth vs. adjusted prior year). Full-year 2026 adjusted diluted EPS guidance: $5.38 to $5.58 (includes $0.20 acquisition-related dilution).</li></ul> Business Highlights <ul><li>Completed acquisition of Exact Sciences on March 23, 2026, establishing Abbott in the oncology diagnostics market and adding Cancer Diagnostics (including Cologuard and Cancerguard) to the Diagnostics segment.</li><li>Reported comparable sales growth of 3.7% for the company; segment comparable performance included Nutrition (comparable decline of 7.7%), Diagnostics (comparable growth of 1.8%), Established Pharmaceuticals (comparable growth of 9.0%), and Medical Devices (comparable growth of 8.5%).</li><li>Medical Devices delivered broad-based operational strength with double-digit reported growth in Electrophysiology, Heart Failure and Rhythm Management, and continued momentum in Diabetes Care continuous glucose monitors.</li><li>Diagnostics performance: Core Laboratory tests increased year-over-year and sequentially; Rapid and Molecular Diagnostics were affected by a weaker respiratory virus season; Cancer Diagnostics growth driven by Cologuard and a multi-cancer screening test launched last year.</li><li>Product and clinical progress: announced collaboration with AtaCor Medical on next-generation EV-ICD system; VERITAS study showed positive early results for the Amulet 360 LAA Occluder; FreeDM2 trial showed clinical benefit for FreeStyle Libre in Type 2 diabetes on basal insulin.</li></ul>Original SEC Filing: ABBOTT LABORATORIES [ ABT ] - 8-K - Apr. 16, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

EXAS

LABU

Abbott reported Q1 2026 results with revenue of $11.16 billion and adjusted diluted EPS of $1.15, a 6% increase year-over-year. The company completed its acquisition of Exact Sciences on March 23, 2026, and updated its 2026 guidance to 6.5%-7.5% sales growth and adjusted EPS of $5.38-$5.58. Abbott declared a quarterly dividend of $0.63 per share. Segment performance included a 9% growth in Established Pharmaceuticals and 8.5% in Medical Devices, while Nutrition saw a decline of 7.7%.

TradingView

Abbott Laboratories

Exact Sciences

Direxion S&P Biotech Bull 3X

iShares US Pharma

VG Health

iShares Genomics Immunology and Healthcare ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares US Healthcare Providers

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Abbott reports Q1 2026: Revenue $11.16B, adjusted diluted EPS $1.15; updates 2026 guidance